TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY
It is estimated that approximately 86,500 new cases of NHL and CLL will be identified in the United States in the year 2014, and 23,590 individuals will die from these diseases. Currently more than 60 drug products with more than 70 distinct FDA-approved indications are labeled for use in the management of hematologic cancers. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These video proceedings from the third part of a 6-part integrated CNE curriculum originally held at the 2014 ONS Annual Congress feature discussions with leading hematology-oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with NHL and CLL.

LEARNING OBJECTIVES

• Provide patient-focused education regarding the available therapeutic agents used in the management of indolent and aggressive forms of B-cell NHL to enhance clinical decision-making.
• Apply the results of emerging clinical research to the therapeutic and supportive care of patients with newly diagnosed and relapsed/refractory NHL and CLL.
• Explain the risks and benefits of evidence-based treatment approaches to patients with T-cell lymphoma requiring systemic therapy.
• Evaluate the preliminary safety profiles and response outcomes of investigational agents and treatment strategies undergoing evaluation in NHL and CLL, and counsel appropriately selected patients about the potential for enrollment in clinical trials.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NHL/CLL to optimize clinical and quality-of-life outcomes.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION
This is a video CNE program. Participants should read the learning objectives and faculty disclosures and watch the video.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Amy Goodrich, CRNP-AC
Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

No real or apparent conflicts of interest to disclose.

Lauren C Pinter-Brown, MD
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Advisory Committee: Celgene Corporation, Spectrum Pharmaceuticals Inc.

Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Advisory Committee: Gilead Sciences Inc, Millennium: The Takeda Oncology Company; Speakers Bureau: Millennium: The Takeda Oncology Company, Seattle Genetics.

Mitchell R Smith, MD, PhD
Director of Lymphoid Malignancies Program at Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Advisory Committee: Cephalon Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Seattle Genetics.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.